The UK and US have established a major trade agreement that will maintain zero tariffs on UK pharmaceutical exports being sold in the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This move ensures that import taxes on these crucial products will be held at zero for a timeframe of 36 months.
This development follows recent warnings to hike import taxes on branded drug products, with increases discussed up to 100%.
"This agreement between the UK strengthens the international landscape for new treatments and introduces much-needed equity to transatlantic pharmaceutical trade," an announcement noted.
Trade Impact
Drugs are one of the UK's largest goods shipped to the United States, which is clearly the biggest buyer for leading UK drugmakers.
Statistics indicate that in the year prior to September, the UK sold drugs valued at over eleven billion pounds to the US. This amount accounted for nearly one-fifth of all goods exports in that span.
"This deal secures work, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a minister commented.
Detailed UK Commitments
The agreement includes several notable changes from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it judges new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to raise overall NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, refunds exceeded 20%.
Recent Tensions
The deal comes amid a long-running dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were intensified by assertions that US consumers were paying significantly more for the identical medicines than people in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
One official stated that the NHS must spend more on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the past decade.
